Plaintiffs Targeting Biologic-Biosimilars Settlements with Pay-for-Delay Antitrust Claims
				Posted 
 04/18/19
										
						By						  
													James J. Kovacs	
												
									
				 
								 				Antitrust principles that can invalidate certain pay-for-delay settlements will be expanding into the new frontier of biologic and biosimilar drugs if plaintiffs in several new suits are successful.
Recently-filed  against AbbVie, manufacturer of a leading biologic drug, Humira, and numerous biosimilar manufacturers are alleging that settlements between the AbbVie and various biosimilar...